Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

489
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
489
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Cancer Vaccines01:30

Cancer Vaccines

345
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
345

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Smart-responsive electrospun scaffolds (SRES) for neural repair: Recent advances and future prospects.

Bioactive materials·2026
Same author

Synthetic Polymers for Drug, Gene, and Vaccine Delivery.

Polymer science & technology (Washington, D.C.)·2026
Same author

Chirality of poly(γ-glutamic acid) directs calcium nanoparticle assembly and adjuvant-like immune activation.

Acta biomaterialia·2026
Same author

A biomietic filamentous hydrogel with enhanced bacteria contact and bactericidal efficiency for the treatment of various skin infections.

Biomaterials·2026
Same author

Biomimetic Mineralized Hydrogels for Bone Regeneration.

Advanced materials (Deerfield Beach, Fla.)·2025
Same author

Raman Spectroscopy for <i>In Vivo</i> Tumor Imaging.

Analytical chemistry·2025

Related Experiment Video

Updated: Jun 11, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.4K

Tumor microenvironment-activated polypeptide nanoparticles for oncolytic immunotherapy.

Zhihui Guo1, Tianze Huang1, Xueli Lv2

  • 1Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, PR China; School of Applied Chemistry and Engineering, University of Science and Technology of China, Hefei, 230026, PR China.

Biomaterials
|October 6, 2024
PubMed
Summary

This study developed pH-sensitive nanoparticles (DNPs) to shield cationic oncolytic polypeptides (PLP). DNPs release PLP in acidic tumor environments, improving cancer cell selectivity and reducing toxicity for effective immunotherapy.

Keywords:
Cancer immunotherapyCationic polypeptideImmunogenic cell deathOncolytic therapypH-sensitivity

More Related Videos

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1&#945; Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

2.0K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

673

Related Experiment Videos

Last Updated: Jun 11, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.4K
Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1&#945; Nanoparticles
09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

2.0K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

673

Area of Science:

  • Biomaterials Science
  • Cancer Immunotherapy
  • Nanomedicine

Background:

  • Cationic oncolytic polypeptides show promise for cancer treatment by directly lysing tumor cells and stimulating antitumor immunity.
  • However, their clinical application is limited by poor tumor selectivity and systemic toxicity due to positive charges.

Purpose of the Study:

  • To develop a tumor microenvironment-responsive nanoparticle (DNP) to enhance the safety and efficacy of cationic oncolytic polypeptides (PLP).
  • To shield the positive charges of PLP and enable targeted release in acidic tumor conditions.

Main Methods:

  • Self-assembly of a cationic oncolytic polypeptide (PLP) with a pH-sensitive anionic polypeptide to form DNPs.
  • Evaluation of DNP stability at physiological pH (7.4) and release profile in acidic tumor microenvironment (pH 6.8).
  • Assessment of DNP-induced immunogenic cell death, in vitro cytotoxicity, and in vivo antitumor efficacy, including inhibition of tumor growth, recurrence, and metastasis.

Main Results:

  • DNPs effectively shielded the positive charges of PLP, enhancing biocompatibility and reducing inherent toxicity.
  • DNPs remained stable at pH 7.4 but released PLP in the acidic tumor microenvironment (pH 6.8).
  • DNPs induced potent immunogenic cell death and demonstrated significant in vivo inhibition of tumor growth, recurrence, and metastasis through direct oncolysis and immune activation.

Conclusions:

  • pH-sensitive DNPs represent a promising strategy to improve the tumor selectivity and biosafety of cationic polypeptides for oncolytic immunotherapy.
  • This nanoparticle system offers a potential platform for targeted delivery of oncolytic agents, enhancing therapeutic outcomes while minimizing side effects.